MediWound Ltd. (MDWD) Stock Price Down 2.2%
MediWound Ltd. (NASDAQ:MDWD) was down 2.2% during trading on Tuesday . The stock traded as low as $7.92 and last traded at $7.98, with a volume of 231,297 shares. The stock had previously closed at $8.16.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of MediWound from a “buy” rating to a “hold” rating in a report on Tuesday, June 28th. Wells Fargo & Co. assumed coverage on shares of MediWound in a report on Wednesday, August 17th. They issued an “outperform” rating and a $14.00 target price on the stock. Finally, Jefferies Group dropped their target price on shares of MediWound from $15.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, July 29th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $13.63.
The firm’s 50-day moving average is $7.52 and its 200-day moving average is $7.71. The company’s market cap is $174.37 million.
MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.11. The business had revenue of $3.36 million for the quarter, compared to analyst estimates of $0.45 million. The company’s revenue for the quarter was up 115.8% on a year-over-year basis. During the same period last year, the firm earned ($0.19) EPS. Equities analysts anticipate that MediWound Ltd. will post ($1.03) earnings per share for the current year.
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.